XML 59 R50.htm IDEA: XBRL DOCUMENT v3.20.2
Omeclamox®-Pak, RediTrex® and Vibativ® - Narrative (Details) - USD ($)
shares in Thousands
 1 Months Ended 12 Months Ended
Oct. 29, 2013
Nov. 30, 2016
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2020
Business Acquisition [Line Items]            
Payments for asset acquisitions     $ 2,300,000      
Revenue from Contract with Customer, Excluding Assessed Tax     32,407,845 $ 28,803,961 $ 25,549,058  
Other revenue, potential upfront payment related to product sales     4,800,000      
Payments to acquire businesses     5,000,000 20,000,000 0  
Amended International Agreement | Pernix Therapeutics            
Business Acquisition [Line Items]            
Other revenue, potential upfront payment related to product sales $ 4,000,000.0   2,300,000      
Omeclamox-Pak            
Business Acquisition [Line Items]            
Revenue from Contract with Customer, Excluding Assessed Tax     800,000 600,000    
Methotrexate            
Business Acquisition [Line Items]            
Payments to acquire businesses   $ 100,000        
Liabilities incurred   $ 900,000        
Stock issued during period, acquisitions     900,000 1,100,000    
Methotrexate | Subsequent Event            
Business Acquisition [Line Items]            
Liability to be paid           $ 1,000,000.0
Omeclamox-Pak            
Business Acquisition [Line Items]            
Revenue from Contract with Customer, Excluding Assessed Tax     $ 837,829 $ 623,297 $ 1,761,868  
Restricted Stock | Methotrexate            
Business Acquisition [Line Items]            
Stock issued during period, acquisitions (in shares)   180